Introduction: Research on the association between electroconvulsive therapy (ECT) and increased brain derived neurotrophic factor (BDNF) levels has produced conflicting result. There have been few studies which have evaluated BDNF levels in clinical contexts where there was remission following treatment. The objective of this study was to investigate whether remission of depression following ECT is associated with changes in BDNF levels. Methods: Adult inpatients in a psychiatric unit were invited to participate in this naturalistic study. Diagnoses were made using the Mini-International Neuropsychiatric Interview (MINI) and symptoms were evaluated at admission and discharge using the Hamilton Rating Scale for Depression (HDRS-17). Thirty-one patients who received a diagnosis of depression and were subjected to ECT were included retrospectively. Clinical remission was defined as a score of less than eight on the HDRS-17 at discharge. Serum BDNF levels were measured in blood samples collected at admission and discharge with a commercial kit used in accordance with the manufacturer's instructions. Results: Subjects HDRS-17 scores improved following ECT (t = 13.29; p = 0.00). A generalized estimating equation (GEE) model revealed a remission × time interaction with BDNF levels as a dependent variable in a Wald chi-square test [Wald 2 = 5.98; p = 0.01]. A post hoc Bonferroni test revealed that non-remitters had lower BDNF levels at admission than remitters (p = 0.03), but there was no difference at discharge (p = 0.16). Conclusion: ECT remitters had higher serum BDNF levels at admission and the level did not vary during treatment. ECT non-remitters had lower serum BDNF levels at admission, but levels increased during treatment and were similar to those of ECT remitters at discharge.
Introduction
Depression is a highly debilitating psychiatric condition that can severely reduce quality of life and may have other serious consequences, such as increasing the risk of suicide (Antunes and Fleck, 2009) . Approximately 50% of patients endure chronic illness and up to 20% have an insufficient response to drug treatments (Fava et al., 2003; Hussain and Cochrane, 2004) .
Persistence of symptoms despite increases in synaptic monoamine levels following treatment with antidepressants ied neurotrophin, plays an important role in neurogenesis and synaptic plasticity and helps to support cell viability (Lee et al., 2002) . BDNF is a protein which is mainly expressed in the central nervous system but mainly stored in blood platelets (Binder and Scharfman, 2004) ; serum levels are 100 times higher than plasma levels (Yamamoto and Gurney, 1990) .
The 'neuroplasticity hypothesis' of depression emerged from evidence for the role of neurotrophins in brain functioning and there the number of clinical trials studying the relationship between depressive disorder and BDNF is increasing (Kotan et al., 2009; Sala et al., 2004; Bilgen et al., 2014) . Several studies, including a meta-analysis, have reported that BDNF levels (serum or plasma) are low in drug-free depressive patients (Karege et al., 2002; Shimizu et al., 2003; Fernandes et al., 2011; Bocchio-Chiavetto et al., 2010; Sen et al., 2008) and increase following antidepressant treatment (Shimizu et al., 2003; Aydemir et al., 2005; Huang et al., 2008a,b; Molendijk et al., 2011; Gönül et al., 2005; Brunoni et al., 2008; Sen et al., 2008; Guilloux et al., 2012; Wolkowitz et al., 2011; Matrisciano et al., 2009; Serra-Millàs et al., 2011) . There is also evidence that BDNF receptor tropomyosin-related kinase B (TrkB) levels are elevated in depression (Hung et al., 2010) . Genetic studies have demonstrated that the most commonly studied polymorphism of BDNF is Val66Met (rs6265), and this polymorphism has been associated with early antidepressant response (Xu et al., 2012) and remission (Taylor et al., 2011) . Despite this research it remains unclear how BDNF is related to improvements in depression. Duman et al. (1997) hypothesized that BDNF induces neuronal sprouting in the hippocampus and cerebral cortex and improves synaptic function and the connectivity of neuronal circuits involved in mood regulation (Duman et al., 1997; Duman and Vaidya, 1998) .
Electroconvulsive therapy (ECT) is the most effective treatment for refractory depression, with effectiveness rates of between 80 and 90% (UK ECT Review Group, 2003) , although its mechanism of action is still unknown. Rodent studies have demonstrated significant increases in BDNF mRNA (Duman et al., 1997; Nibuya et al., 1995) and BDNF protein (Altar et al., 2004) following administration of ECT to several brain areas.
Although there have been several studies in humans suggesting that BDNF levels increase following ECT (Bocchio-Chiavetto et al., 2006; Marano et al., 2007; Okamoto et al., 2008; Piccinni et al., 2009; Hu et al., 2010; Haghighi et al., 2013; Bilgen et al., 2014; Salehi et al., 2014) , and a recent meta-analysis reached the same conclusion (Brunoni et al., 2014) , there is also a considerable body of data in which there was no association (Grønli et al., 2009; Fernandes et al., 2009; Gedge et al., 2012; Lin et al., 2013; Stelzhammer et al., 2013) . The differences in results may be due to methodological differences including use of medication during the study, the time lapse between the conclusion of ECT treatment and blood testing, whether BDNF was measured in serum or plasma, differences in ECT protocols etc. Given the conflicting results it is not yet possible to draw firm conclusions about the relationships between BDNF, depression and ECT. Few of the studies which reported an association between BDNF levels and ECT evaluated BDNF levels in clinical contexts where there was remission following treatment. Piccinni et al. (2009) found that remitters had higher BDNF levels than non-remitters at baseline and one week after the end of ECT treatment. In relation to clinical measures other than remission, Okamoto et al. (2008) found that in responders to ECT serum BDNF levels increased following treatment, whereas those of nonresponders were unchanged. Other studies have, however, found no correlation between scores on depressive symptom scales and BDNF levels (Fernandes et al., 2009; Haghighi et al., 2013) . A recent investigation of the association between serum BDNF levels and clinical improvement following ECT in treatment-resistant depression (Rapinesi et al., 2015) found that in patients who had reduced symptom score following ECT serum BDNF levels were low at baseline and did not change following ECT.
The research discussed above suggests that BDNF is a potential biomarker for depression, but the evidence on whether levels are modified by pharmacotherapy and ECT and the relationship between BDNF levels and clinical outcome is unclear. The objective of this naturalistic study was to investigate whether clinical outcome are associated with changes in BDNF levels following ECT for depression. In this study the clinical outcome measured was remission of symptoms after ECT treatment. We hypothesized that patients who showed remission following ECT would have higher BDNF levels than non-remitters at baseline and at the conclusion of treatment.
Methods
This was a naturalistic, prospective cohort study which analyzed differences between the serum BDNF levels of ECT remitters and non-remitters. It forms part of a larger study called 'Evaluation and follow-up of patients with severe mental illness: diagnostic factors, prognosis and treatment and its association with biological markers'. It received approval from the Ethical and Scientific Committee of the Hospital de Clínicas de Porto Alegre (Grupo de Pesquisa e Pós-graduaç ão register no 10-0265). Informed consent to participate of the study was obtained from all participants. In cases where the patient was competent to provide consent written informed consent was provided by him or her; in the cases that patient was not competent to provide consent, a relative over 18 years old was approached to provide written consent to the patient's participation.
Subjects
Patients aged at least 18 years old who were admitted to a psychiatric unit (Hospital de Clínicas de Porto Alegre, Porto Alegre, Southern Brazil) for inpatient treatment between May 2011 and April 2013 were invited to participate in this study.
After consent to participation was obtained, a psychiatric diagnosis was made by psychiatrists not involved in patient care using the MINI (Sheehan et al., 1998) , and symptoms were evaluated using the 17-item version of the Hamilton Depression Rating Scale (HDRS-17; Hamilton, 1960) . Inpatients diagnosed with depression, with or without psychotic features, were monitored until discharge.
Prior to discharge, inpatients were re-evaluated and excluded from the study if their hospital stay had lasted less than seven days or they were dependent on drugs or alcohol. Patients were also excluded from the study if they were pregnant or breast-feeding, or had suffered from an acute or chronic infection, autoimmune condition, neoplastic or endocrine disease, myocardial infarction or other major cardiovascular disorders in the last six months because these conditions have the potential to influence BDNF levels. Finally, we reviewed the treatment patients had received and included only those who undergone ECT.
At this point we re-evaluated the symptoms of subjects included in the study. Clinical remission was defined as a score of less than eight on the HDRS-17 (Frank et al., 1991) .
Electroconvulsive therapy
ECT was prescribed by the assistant psychiatrist, who was not part of the research team, and was only administered in cases where informed consent for ECT had been obtained. Where patients were not competent to provide informed consent, written consent was sought from a relative aged over 18 years.
Indications for ECT were based on the Report of the Task Force (APA, 2001). Primary indications include the need for a rapid response or a higher probability of response than is offered by pharmacotherapies, severe medical illness, risk of harm to self or others, the patient's medical status, treatment history and treatment preference. Secondary indications are lack of clinical response, intolerance of side effects and a deterioration in psychiatric condition.
Before ECT patients were screened for general medical conditions using a physical examination, routine blood tests and an electrocardiogram (ECG).
The ECT procedure was performed as follows: Three times a week, with high-dose (six times the convulsive threshold), briefpulse, right unilateral using the d'Elia position (Prudic et al., 2004; Lane et al., 1989) . Thiopental (3 mg/kg intravenously) was used as an anesthetic and succinylcholine (1 mg/kg intravenously) as a muscle relaxant. The ictal response was recorded using electroencephalography (EEG) and an adequate seizure was defined as an EEG seizure lasting at least 25 s with a myoclonus of at least 20 s.
The number of ECT sessions for individual patients was determined by the assistant psychiatrist on the basis of individual response to treatment. Patients received concomitant psychopharmacotherapy based on the general principle of combining two antidepressants with different mechanisms of action, potentiation with different strategies (e.g. atypical antipsychotics) or changing to a different antidepressant from that the patient had been receiving prior to admission. Decisions about drug treatment were made on a purely clinical basis by an assistant psychiatrist who was not part of the research team.
BDNF serum levels
Ten milliliters of blood were withdrawn by venipuncture into a free-anticoagulant vacuum tube from each subject on admission to the psychiatric unit (T0) before the ECT procedures described above, including the administration of anesthetic and muscle relaxant drugs; blood was also collected at discharge from the psychiatric unit after ECT treatment (T1). The blood was centrifuged at 4000g for 10 min and serum was stored −80 • C. All samples from both time points were analyzed together, on the same date, at the same time, using the same kit.
BDNF serum levels were measured with sandwich enzymelinked immunosorbent assay (ELISA), using a commercial kit (Milipore, USA) in accordance with the manufacturer's instructions. In brief, microtiter plates (96-well; flat-bottom) were coated for 24 h at 4 • C with the samples diluted 1:100 in sample diluent and standard curve ranging from 7.8 to 500 pg of BNDF. Plates were then washed four times with wash buffer followed by the addition of biotinylated mouse anti-human BNDF monoclonal antibody (diluted 1:1000 in sample diluent), and then incubated at room temperature for 3 h. After washing, a second incubation with streptavidin-horseradish peroxidase conjugate solution (diluted 1:1000) was carried out at room temperature for 1 h. After addition of substrate and stop solution the BDNF content was determined (absorbance set at 450 nm). The standard curve demonstrates a direct relationship between optical density (OD) and BDNF concentration. All samples were subjected to a single assay and the results are expressed in ng/mL.
Statistical analyses
The Shapiro-Wilk test was used to determine normality. Where variables were not normally distributed the Mann-Whitney U-test was used to compare means. Dependent or independent t-tests were used to compare the means of normally distributed variables. Categorical variables were analyzed using the chi-square test.
A generalized estimating equation (GEE) model was used to analyze effects of time (admission, T0; discharge, T1), remission (binary variable; defined in terms of HDRS-17 score), and the interaction between them, with BDNF levels as the dependent variable. The Bonferroni test was used for post hoc analyses.
Data were expressed as mean ± SD and results with p ≤ 0.05 (2-tailed) were considered significant. Analyses were carried out using the Statistical Package for the Social Sciences (SPSS) version 20.0.
Results
Thirty-one subjects were included in the study. Following treatment the sample showed an improvement in symptoms of depression, as measured by HDRS-17 (T0: M = 26.04 ± 6.62, T1: M = 8.41 ± 4.51; t = 13.29; p = 0.00).
Eleven subjects (35.48%) had missing remission data. Eleven of the remaining 21 subjects (52.38%) were remitters and 10 (47.62%) were non-remitters. In order to establish whether there were differences between participants for whom remission information was and was not available, we compared the two groups in terms of age, sex and baseline HDRS-17 score. There were no group differences in age (missing data group: M = 48.00 years ± 14.85; full data group: M = 48.75 years ± 15.40; t = 0.11; p = 0.90), or sex (missing data group: women = 5 (62.5%); full data group: women = 19 (90.5%); 2 = 3.17, p = 0.11). Subjects for whom remission data were not available did, however, have lower baseline HDRS-17 scores (missing data group: M = 17.80±6.61; full data group: M = 26.45 ± 6.83; t = 2.54, p = 0.01).
There were no difference between remitters and non-remitters in terms of age, gender, diagnosis (unipolar or bipolar depression; psychosis), use of medication, baseline HDRS-17 score or number of ECT sessions (see Table 1 ).
In ECT remitters BDNF levels at baseline and discharge were similar (T0 = 47.30 ± 20.31; T1 = 42.09 ± 11.69; t = 0.66; p = 0.52); however in non-remitters levels changed between T0 and T1 (T0 = 35.02 ± 10.99; T1 = 51.56 ± 15.98; t = −2.82; p = 0.02).
A GEE model was calculated, with time (T0; T1) and remission in terms of HDRS-17 score after ECT (yes; no) as factors; the dependent variable was BDNF level. There was a remission × time interaction for BDNF levels in the Wald chi-square test (Wald 2 = 5.98; p = 0.01).
A post hoc Bonferroni test confirmed that non-remitters had lower baseline BDNF levels than remitters (p = 0.03), however at T1, i.e. following completion of treatment, levels in the two groups were similar (p = 0.16). Per group GEE analysis corroborated the results of the t-tests, indicating that BDNF levels were different at T0 and T1 in non-remitters (p = 0.00) but not in remitters (p = 0.43) (see Fig. 1 ).
Discussion
This naturalistic study showed that the depressive symptoms of patients who underwent ECT improved following treatment. There was a remission by time interaction with respect to BDNF levels. Remitters had a higher mean BDNF level than non-remitters at baseline, and it did not vary during treatment. Although nonremitters had a lower mean BDNF level at baseline, it improved during treatment and at discharge was similar to that of remitters.
Only one previous study has analyzed BDNF levels and remission following ECT and like this study it found that ECT remitters had higher baseline BDNF levels than ECT non-remitters, suggesting that higher plasma BDNF levels are associated with a positive remission to treatment (Piccinni et al., 2009) . Taking together our results and the Piccinni et al. (2009) results, a possible hypothesis could be that higher levels of BDNF at baseline could predict remission for ECT. 28.10 ± 6.27 t = −1.08 0.29 ECT = electroconvulsive therapy; SD = standard deviation; 2 = Chi square test; SSRI = selective serotonin reuptake inhibitor; SNRI = serotonin and norepinephrine reuptake inhibitors; NDRI = norepinephrine and dopamine reuptake inhibitor; TCA = tricyclic antidepressants; AAP = atypical antipsychotics; TAP = typical antipsychotics; MS = mood stabilizers; BDZ = benzodiazepines; HDRS-17 = Hamilton depression rating scale 17 Items; CGI = the clinical global impressions scale. Piccinni et al. (2009) also found that remitters' BDNF levels increased during the course of the study and thus remained different from those of non-remitters at the end of the study. In this study, however, we found that remitters' BDNF levels did not change over time although those of non-remitters did increase during treatment and were similar to those of remitters by the time of discharge. The mechanism underlying this increase in BDNF levels in the group which had a less favorable clinical outcome is unclear.
As there are few published studies of remission and BDNF levels in patients who undergo ECT for depression this discussion refers to research using other measures of clinical outcome. Analysing clinical response (improvement of 50% of symptoms in depression rating scales), Okamoto et al. (2008) found that BDNF levels increased in responders to ECT in comparison to non-responders. A similar study of patients who received the antidepressant duloxetine alongside ECT (Mikoteit et al., 2014) found that higher baseline serum BDNF level predicted a positive clinical outcome at the end of the study (after 6 weeks), whereas increase in BDNF level during treatment was not associated with treatment outcome. The other unexpected finding of this study was that more severe depression was associated with higher baseline BDNF levels. Haghighi et al. (2013) compared plasma BDNF levels in a group of patients with depression receiving citalopram at 40 mg/day and another group receiving drug treatment plus 12 sessions of ECT.
Plasma BDNF increased over time in both groups; the combined treatment group had a higher difference in the increase of plasma BDNF. Both groups showed similar reductions in scores on the Beck Depression Inventory scores and HDRS-17 scores following treatment.
A study which investigated the effects of ECT on serum BDNF levels in patients with treatment-resistant major depression found that HDRS-17 scores were lower and mean BDNF level was higher after ECT (Bilgen et al., 2014) . Rapinesi et al. (2015) reported that in patients with treatment-resistant depression ECT reduced symptom scores, but did not affect serum BDNF levels; there was no correlation between change in serum BDNF level and changes in symptom scale scores. Serum BDNF levels were low both at baseline and after ECT. These results do not support the hypothesis that improvements in depression following ECT are mediated by increases in serum BDNF levels.
Recent evidence suggests that ketamine infusions have a rapid antidepressant effect that may be tracked by changes in peripheral BDNF levels (Duncan et al., 2013; Haile et al., 2014) . A study comparing serum BDNF levels and clinical response after ketamine infusions and ECT (Allen et al., 2015) found that ketamine transiently increased serum BDNF in symptomatic responders one week after the first infusion, but subsequent infusions did not produce a similar increase nor any other response that could be related to changes in symptoms. Improvement in symptoms following ECT was not associated with changes in BDNF serum levels.
Taken together these studies fail to provide clear evidence of an association between ECT, BDNF levels and clinical outcome. BDNF is only one of a number of molecules which have been suggested to be involved in depression. The association between changes in BDNF levels and changes in symptoms is not linear (Haghighi et al., 2013) ; it is much more complex than was previously thought and may involve other psychoneuroendocrine mechanisms and genetic factors such as promoter methylation of the BDNF gene (Kleimann et al., 2015) or BDNF gene polymorphisms (Bousman et al., 2015) . An investigation of the links between neuroendocrine pathways and psychological processes (Hibel et al., 2013) showed that cortisol secretion was not associated with symptom improvement in depressive patients. These studies suggest that if there is a link between a biological pathway and clinical outcome in depression, it is complex and is probably neither unique to depression nor universally applicable.
As one would expect in a naturalistic study, the patients in our sample were prescribed a diverse range of medications alongside their ECT. Despite evidence that antidepressants influence BDNF levels (Sen et al., 2008) we found no differences between remitters and non-remitters with respect to type of medication used (see Table 1 ).
An important limitation of this study is the small sample size. Previous similar studies have used similar or larger samples. To confirm the finding that remission following ECT is correlated with higher baseline BDNF level further research using a larger sample is required.
The lack of increase in BDNF levels in remitters following ECT might be due to the timing of the second evaluation. BocchioChiavetto et al. (2006) found that the increase in BDNF levels only reached significance one month after completion of ECT, whereas Hu et al. (2010) demonstrated this difference after two weeks. In our study the post-treatment assessment of BDNF levels was carried out at the time of discharge and, like Grønli et al. (2009) , we found no increase in BDNF levels among remitters. Stelzhammer et al. (2013) assessed BDNF levels six hours after ECT, Fernandes et al. (2009) and Lin et al. (2013) measured BDNF levels one day after the end of ECT, and Gedge et al. (2012) made their assessment one week after treatment was completed. None of these studies reported an increase in BDNF levels.
The lack of long-term, post-treatment measurements of BDNF levels are a further limitation. The missing data is a weakness of the study; subjects with missing information had lower baseline HDRS-17 scores at baseline than those for who we obtained complete data sets, but this does not appear to have affected the main findings.
Conclusion
Patients who underwent ECT for depression subsequently showed an improvement in symptoms. Patients who achieved remission of depression following ECT had higher baseline serum BDNF levels than those who did not; their BDNF levels did not change during treatment. Although non-remitters had lower baseline BDNF levels, their levels improved during treatment. These results suggest that the relationship between BDNF, depression and clinical response to ECT is complex.
